A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Status:
RECRUITING
Trial end date:
2030-05-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, open-label, multicenter Phase I/II study of MHB036C combined with MHB039A or other anti-tumor therapy in patients with advanced lung cancer. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MHB036C combined with MHB039A or other anti-tumor therapies.